Mark R. Litzow, MD, is a professor of medicine in the Division of Hematology at Mayo Clinic.
Upfront Immunotherapy Approaches Improve Outcomes in ALL
Recent advancements have improved the way physicians treat acute lymphoblastic leukemia.
Rationale for a Trial of Blinatumomab in MRD-Negative ALL
Mark R. Litzow, MD, discusses the purpose of a trial of blinatumomab for patients with newly diagnosed B-lineage acute lymphoblastic leukemia.
Incorporating Pediatric Regimens in the Treatment of ALL
Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
The Role of Transplants in Patients With ALL
Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses the role of transplant in patients with acute lymphoblastic leukemia (ALL).
Assessing Minimal Residual Disease in Patients With ALL
Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting minimal residual disease (MRD) assessments in patients with ALL.